Amylyx Pharmaceuticals, Inc. (AMLX) › Operating Cash FlowAmylyx Pharmaceuticals, Inc. (AMLX) — Operating Cash FlowAnnual figures by period end, from SEC filings.2021-12-31: -$74.80M2022-12-31: -$179.87M2023-12-31: $11.92M2024-12-31: -$167.65M2025-12-31: -$123.34M-$123.34M2021-12-31Operating Cash Flow (USD)2025-12-31Period endedOperating Cash FlowChange YoYSource filing2025-12-31-$123.34M—2026-03-03From 2025-01-012024-12-31-$167.65M-1506.6%2026-03-03From 2024-01-012023-12-31$11.92M—2025-03-04From 2023-01-012022-12-31-$179.87M—2024-02-22From 2022-01-012021-12-31-$74.80M—2024-02-22From 2021-01-01Other metrics: RevenueCost of RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityCash & EquivalentsCapital ExpendituresShares OutstandingDividends Per ShareWeighted Average Diluted SharesEPS (Basic)